OncoMatch/Clinical Trials/NCT06332430
Intratumoral CAN2109 in Subjects With Solid Tumors
Is NCT06332430 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CAN2109 for solid tumor.
Treatment: CAN2109 — A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Unstable/inadequate cardiac function defined as: NYHA Class 3 or 4 congestive heart failure, uncontrolled hypertension, acute coronary syndrome within 6 months, clinically important cardiac arrhythmia, mean QTc > 480 ms
Unstable/inadequate cardiac function defined as follows: New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled hypertension, acute coronary syndrome within 6 months, clinical important cardiac arrhythmia, mean corrected QT (QTc) interval corrected for heart rate > 480 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify